First-in-human ER-100 data support dose escalation, with early visual-field signals in two of three glaucoma patients.

Link as first comment.

#longevity #geroscience #ER100 #glaucoma #clinicaldata

The Phase 1 trial of ER-100, which activates Yamanaka factors in the eye, did not cause serious adverse events in three participants. Early visual field signals were observed in two of the three patients with open-angle glaucoma.

#PartialReprogramming #ER100 #Glaucoma